Novel Enzyme Discovered That Plays Vital Role In Insulin Secretion

By on May 26, 2014

A new study has identified a new novel enzyme, which plays a vital role in insulin secretion and type 2 diabetes treatment.

According to this study, this enzyme helps in improving the signal which helps in better secretion of insulin and there by controlling high blood sugar levels (hyperglycemia) in type 2 diabetes animal model.

This novel enzyme was discovered by CHUM Research Centre (CRCHUM) and University of Montreal researchers, which is a part of Montreal Diabetes Research Center. The research team of this study was directed by researchers Marc Prentki and Murthy Madiraju.


Novel Enzyme - Insulin SecretionActually, insulin is the main hormone that is responsible for controlling of blood glucose levels, and fat utilization in our body. When the beta-cells in pancreas releases insufficient amount of insulin, it results in development of types 2 diabetes.

This secretion of insulin is dependent on the pancreatic beta-cells utilization of glucose, and fat, and also on the production of novel signal. This novel signal, which is discovered by the researches of this study is named as monoacylglycerol.

Marc Prentki, who is one of the directors of this study, is the Director of the Montreal Diabetes Research Centre and Professor at the University of Montreal. Marc Prentki holds the Canada Research Chair in Diabetes and Metabolism.

Marc Prentki said that even though there is significant research related to the secretion of insulin into the blood, but the signal molecules, which are involved in the process was unknown and identifying these signals is very helpful to develop better treatment for diabetes.

Murthy Madiraju, who is another director of this study, is a researcher at the CRCHUM. Murthy Madiraju said that when pancreatic glucose cells utilize glucose for secretion of insulin, it produces a fat like signal called as monoacylglycerol. This signal is plays a vital role in insulin secretion by the pancreatic glucose cells.

The researchers of this study had an enzyme, which is called as alpha/beta hydrolase domain-6 (ABHD6). This enzyme breaks down monoacylglycerol, which results in negatively controlling the release of insulin into the blood.

According to the researchers, an ideal drug for treating type-2 diabetes would raise the levels of insulin by enhancing the pancreatic beta-cells utilization of glucose only when it is elevated and also increase the sensitivity of body tissues to insulin.

Researchers also said that this is what is done by the ABHD6 inhibition, and thus a new unique target with regards to type-2 diabetes is identified.

Presently, the researchers of this study are trying to discover a new blocker that works effectively on ABHD6, and also doesn’t cause any unwanted toxicity. Thereby developing a new effective drug that can be used for treating type 2 diabetes.

Get the latest health Information and Health Tips from!

Delivered by E Healthy Blog

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.

This site uses Akismet to reduce spam. Learn how your comment data is processed.